Jf. Seymour et al., Therapeutic efficacy of granulocyte-macrophage colony-stimulating factor in patients with idiopathic acquired alveolar proteinosis, AM J R CRIT, 163(2), 2001, pp. 524-531
Alveolar proteinosis (AP) is characterized by excessive surfactant accumula
tion, and most cases are of unknown etiology. Standard therapy for AP is wh
ole-lung lavage, which may not correct the underlying defect. Because the h
ematopoietic cytokine granulocyte-macrophage colony-stimulating factor (GM-
CSF) is required for normal surfactant homeostasis, we evaluated the therap
eutic activity of CM-CSF in patients with idiopathic AP. Fourteen patients
received 5 mug/kg/d CM-CSF for 6 to 12 wk with serial monitoring of the alv
eolar-arterial oxygen gradient ([A-a]Do(2)), diffusing capacity of carbon m
onoxide, computed tomographic scans, and exercise testing. Patients not res
ponding to 5 mug/kg/d CM-CSF underwent stepwise dose escalation, and respon
ding patients were retreated at disease recurrence. Stored pretreatment ser
a were assayed for CM-CSF-neutralizing autoantibodies. According to prospec
tive criteria, five of 14 patients responded to 5 mug/kg/d GM-CSF, and one
of four patients responded after dose escalation (20 mug/kg/d). The overall
response rate was 43% (mean improvement in [A-a]Do(2) = 23.2 mm Hg). Respo
nses lasted a median of 39 wk, and were reproducible with retreatment. CM-C
SF was well-tolerated, with no late toxicity seen. The only treatment-relat
ed factor predictive of response was CM-CSF-induced eosinophilia (p = 0.01)
. Each of 12 patients tested had GM-CSF-neutralizing autoantibodies present
in pretreatment serum. We conclude that GM-CSF has therapeutic activity in
idiopathic AP, providing a potential alternative to whole-lung lavage.